BioSpace News Archive

The Olympus POWERSEAL™ 5mm Curved Jaw Sealer/Divider, Double-Action won the 2022 GOOD DESIGN® Award within the Medical Category.

DelveInsight’s ‘Methicillin-Resistant Staphylococcus aureus Infection Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline methicillin-resistant Staphylococcusaureus infection therapies in various stages of clinical development.

Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117.

Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6, 2023.

Novavax, Inc. announced that it has granted a non-qualified stock option and restricted stock units to John C. Jacobs, its newly appointed President and Chief Executive Officer, as a material inducement for his entry into employment with Novavax, effective as of January 23, 2023, the first date of his employment with Novavax.

ReLive Biotechnologies, Ltd., taking over the global patent rights of its flagship products “Spherox” and “Chondrosphere”.

Medtronic plc recently became aware that TRC Capital Investment Corporation has made an unsolicited mini-tender offer to purchase up to 1,500,000 Medtronic ordinary shares, representing approximately 0.1% of the company’s outstanding ordinary shares.

Daewoong Pharmaceutical’s Fexuclue is attracting attention as a game changer in the global gastroesophageal reflux disease treatment market as it applied for approval in 11 countries across the world within one year after approval in Korea.

Cell BioEngines Inc. announced that it has entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai, in New York, NY for the development and worldwide commercialization rights relating to intellectual property for differentiating most potent immune cell from stem cells and large-scale manufacturing.

iNtRON Biotechnology has announced that it has completed the efficacy evaluation study of BAL200, a novel endolysin-based biologic for the treatment of ‘Inhalational Anthrax’, which was granted an Orphan Drug Designation by the US FDA.